Lineage Cell (LCTX) has been beaten down lately with too much selling pressure. While the stock has lost 43.1% over the past four weeks, there is light at the end of the tunnel as it is now in ...

Ratings for Lineage Cell Therapeutics LCTX were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below provides a snapshot of their ...